Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

The clinical utilization of radiation therapy in Korea between 2009 and 2013

  • Kang, Jin-Kyu (Department of Radiation Oncology, Korea Institute of Radiological & Medical Sciences) ;
  • Kim, Mi-Sook (Department of Radiation Oncology, Korea Institute of Radiological & Medical Sciences) ;
  • Jang, Won-Il (Department of Radiation Oncology, Korea Institute of Radiological & Medical Sciences) ;
  • Seo, Young Seok (Department of Radiation Oncology, Korea Institute of Radiological & Medical Sciences) ;
  • Kim, Hee Jin (Radiation Medicine Policy Development Center, Korea Institute of Radiological & Medical Sciences) ;
  • Cho, Chul Koo (Department of Radiation Oncology, Korea Institute of Radiological & Medical Sciences) ;
  • Yoo, Hyung Jun (Department of Radiation Oncology, Korea Institute of Radiological & Medical Sciences) ;
  • Paik, Eun Kyung (Department of Radiation Oncology, Korea Institute of Radiological & Medical Sciences) ;
  • Cha, Yu Jin (Department of Radiation Oncology, Korea Institute of Radiological & Medical Sciences) ;
  • Song, Hyun Jin (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University)
  • Received : 2016.04.01
  • Accepted : 2016.06.17
  • Published : 2016.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: The purpose of this study was to estimate the clinical utilization of radiation therapy (RT) in Korea between 2009 and 2013. Materials and Methods: We analyzed open claims data from the Health Insurance Review and Assessment Service. The subjects were patients who had diagnostic codes C00-C97 or D00-D48 according to the 10th revision of the International Classification of Diseases, with procedure codes indicating RT treatment. Results: The total number of patients who received RT in 2009, 2010, 2011, 2012, and 2013 were 45,571, 49,593, 54,671, 59,172, and 61,485, respectively. Among them, the total numbers of male and female patients were 20,780/24,791 in 2009, 22,711/26,882 in 2010, 24,872/29,799 in 2011, 27,101/32,071 in 2012, and 27,941/33,544 in 2013. The five cancers that were most frequently treated with RT between 2009 and 2012 were breast, lung, colorectal, liver, and uterine cervical cancers. However, the fifth most common cancer treated with RT that replaced uterine cervical cancer in 2013 was prostate cancer. The three leading types of cancer among the male patients were lung, colorectal, and liver cancers, whereas in female patients, they were breast, uterine cervical, and lung cancers. The type of cancer most commonly treated by RT was cancer of the central nervous system in patients aged 20 years or less, breast cancer in patients aged 30-50 years, and lung cancer in patients aged 60 years or more. Conclusion: Data from this study provided the clinical utilization of RT in Korea between 2009 and 2013.

Keywords

References

  1. Jung KW, Won YJ, Kong HJ, Oh CM, Seo HG, Lee JS. Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010. Cancer Res Treat 2013;45:1-14. https://doi.org/10.4143/crt.2013.45.1.1
  2. Jung KW, Won YJ, Kong HJ, Oh CM, Lee DH, Lee JS. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2011. Cancer Res Treat 2014;46:109-23. https://doi.org/10.4143/crt.2014.46.2.109
  3. Jung KW, Won YJ, Kong HJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. Cancer Res Treat 2015;47:127-41. https://doi.org/10.4143/crt.2015.060
  4. Oh CM, Won YJ, Jung KW, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2013. Cancer Res Treat 2016;48:436-50. https://doi.org/10.4143/crt.2016.089
  5. Lee TJ, Kim S, Cho HJ, Lee JH. The incidence of thyroid cancer is affected by the characteristics of a healthcare system. J Korean Med Sci 2012;27:1491-8. https://doi.org/10.3346/jkms.2012.27.12.1491
  6. Suh M, Choi KS, Park B, et al. Trends in cancer screening rates among Korean men and women: results of the Korean National Cancer Screening Survey, 2004-2013. Cancer Res Treat 2016;48:1-10. https://doi.org/10.4143/crt.2014.204
  7. Yoo SY, Kim MS, Ji YH, Cho CK, Yang KM, You HJ. Statistics for Department of Radiation Oncology (1999-2001). J Korean Soc Ther Radiol Oncol 2004;22:234-6.
  8. Kim MS, Ji YH, You SY, Cho CK, Yang KM, Ryu HJ. National statistics of radiation oncology in Korea (2002-2004). J Korean Soc Ther Radiol Oncol 2006;24:77-80.
  9. Kim MS, Ji YH, You SY, et al. National statistics of radiation oncology in Korea (2005). J Korean Soc Ther Radiol Oncol 2006;24:207-9.
  10. Ji YH, Kim MS, You SY, You DH, Choi MS, Jung HJ. National statistics of radiation oncology in Korea (2006). J Korean Soc Ther Radiol Oncol 2008;26:131-3.
  11. Kang JK, Kim MS, Jang WI, et al. The clinical status of radiation therapy in Korea in 2009 and 2013. Cancer Res Treat 2015 Dec 14 [Epub]. http://dx.doi.org/10.4143/crt.2015.370.
  12. Jung KW, Park S, Kong HJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2009. Cancer Res Treat 2012;44:11-24. https://doi.org/10.4143/crt.2012.44.1.11
  13. Delaney G, Jacob S, Featherstone C, Barton M. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer 2005;104:1129-37. https://doi.org/10.1002/cncr.21324
  14. Jaen Olasolo J, Alonso Redondo E, Exposito Hernandez J, de las Penas Cabrera MD, Cabrera Roldan P. Evidence-based estimation and radiotherapy utilisation rate in Andalusia. Clin Transl Oncol 2007;9:789-96. https://doi.org/10.1007/s12094-007-0141-1
  15. Barton MB, Jacob S, Shafiq J, et al. Estimating the demand for radiotherapy from the evidence: a review of changes from 2003 to 2012. Radiother Oncol 2014;112:140-4. https://doi.org/10.1016/j.radonc.2014.03.024
  16. Borras JM, Lievens Y, Dunscombe P, et al. The optimal utilization proportion of external beam radiotherapy in European countries: an ESTRO-HERO analysis. Radiother Oncol 2015;116:38-44. https://doi.org/10.1016/j.radonc.2015.04.018
  17. Rosenblatt E, Barton M, Mackillop W, et al. Optimal radiotherapy utilisation rate in developing countries: an IAEA study. Radiother Oncol 2015;116:35-7. https://doi.org/10.1016/j.radonc.2015.06.012
  18. Mackillop WJ, Kong W, Brundage M, et al. A comparison of evidence-based estimates and empirical benchmarks of the appropriate rate of use of radiation therapy in Ontario. Int J Radiat Oncol Biol Phys 2015;91:1099-107. https://doi.org/10.1016/j.ijrobp.2014.11.026

Cited by

  1. Recurrence outcomes after omission of postoperative radiotherapy following breast-conserving surgery for ductal carcinoma in situ of the breast: a multicenter, retrospective study in Korea (KROG 16-02 vol.162, pp.1, 2017, https://doi.org/10.1007/s10549-017-4111-1
  2. Quality assurance for a multicenter Phase II study of stereotactic ablative radiotherapy for hepatocellular carcinoma ≤5 cm: a planning dummy run vol.47, pp.6, 2016, https://doi.org/10.1093/jjco/hyw156
  3. Selective Radiation Therapy for Ductal Carcinoma In Situ Following Breast-Conserving Surgery According to Age and Margin Width: Korean Radiation Oncology Group 11-04 and 16-02 Studies vol.20, pp.4, 2016, https://doi.org/10.4048/jbc.2017.20.4.327
  4. Incorporating Risk Factors to Identify the Indication of Post-mastectomy Radiotherapy in N1 Breast Cancer Treated with Optimal Systemic Therapy: A Multicenter Analysis in Korea (KROG 14-23) vol.49, pp.3, 2017, https://doi.org/10.4143/crt.2016.405
  5. Locoregional relapse after gastrectomy with D2 lymphadenectomy for gastric cancer vol.104, pp.7, 2016, https://doi.org/10.1002/bjs.10502
  6. Gamma Evaluation with Portal Dosimetry for Volumetric Modulated Arc Therapy and Intensity-Modulated Radiation Therapy vol.28, pp.2, 2017, https://doi.org/10.14316/pmp.2017.28.2.61
  7. Possible benefits from post-mastectomy radiotherapy in node-negative breast cancer patients: a multicenter analysis in Korea (KROG 14-22) vol.8, pp.35, 2016, https://doi.org/10.18632/oncotarget.16241
  8. Intensity-modulated radiotherapy for hepatocellular carcinoma: dosimetric and clinical results vol.8, pp.35, 2017, https://doi.org/10.18632/oncotarget.19219
  9. A Pilot Study of the Scanning Beam Quality Assurance Using Machine Log Files in Proton Beam Therapy vol.28, pp.3, 2016, https://doi.org/10.14316/pmp.2017.28.3.129
  10. Valproic Acid Sensitizes Hepatocellular Carcinoma Cells to Proton Therapy by Suppressing NRF2 Activation vol.7, pp.None, 2016, https://doi.org/10.1038/s41598-017-15165-3
  11. Value of imaging study in predicting pelvic lymph node metastases of uterine cervical cancer vol.35, pp.4, 2016, https://doi.org/10.3857/roj.2017.00206
  12. Malignant and borderline phyllodes tumors of the breast: a multicenter study of 362 patients (KROG 16-08) vol.171, pp.2, 2018, https://doi.org/10.1007/s10549-018-4838-3
  13. Which Patients with Left Breast Cancer Should be Candidates for Heart-Sparing Radiotherapy? vol.21, pp.2, 2018, https://doi.org/10.4048/jbc.2018.21.2.206
  14. Patterns of Practice in Radiotherapy for Breast Cancer in Korea vol.21, pp.3, 2016, https://doi.org/10.4048/jbc.2018.21.e37
  15. A Survey of Radiation Therapy Utilization in Korea from 2010 to 2016: Focusing on Use of Intensity-Modulated Radiation Therapy vol.33, pp.9, 2018, https://doi.org/10.3346/jkms.2018.33.e67
  16. The Clinical Utilization of Radiation Therapy in Korea between 2011 and 2015 vol.50, pp.2, 2016, https://doi.org/10.4143/crt.2017.096
  17. Estimation of the medical need for carbon-ion radiotherapy in Korea vol.59, pp.5, 2016, https://doi.org/10.1093/jrr/rry046
  18. Breast Conservation Therapy Versus Mastectomy in Patients with T1-2N1 Triple-Negative Breast Cancer: Pooled Analysis of KROG 14-18 and 14-23 vol.50, pp.4, 2018, https://doi.org/10.4143/crt.2017.575
  19. Clinical utilization of radiation therapy in Korea, 2016 vol.61, pp.2, 2016, https://doi.org/10.1093/jrr/rrz095